New Drug for IBD Designed Using Generative AI | Docwire News
The early discovery of the preclinical candidate nomination took only 12 months.
Related Articles
ASCO GU Research to Watch: Bladder Cancer | GU Oncology Now
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CheckMate 274, NIAGRA, and more.
Bonus Episode: Dr. Kavitha Chinnaiyan on Ayurvedic Medicine, Yoga, and Heart Health
Podcast Episode · Heart Doc VIP with Dr. Joel Kahn · 02/14/2025 · 38m
Blood test promises safer heart attack prevention
A simple scoring system could revolutionize how doctors prevent heart attacks and strokes by identifying patients most likely to benefit from preventive medications, according to…
7 surprising ApoB truths about heart health risks
ApoB is emerging as a crucial piece of the heart health puzzle, even as sophisticated machines whir and beep with promises of precise diagnoses in…
How to Avoid Heart Disease: 8 Lifestyle Changes You Can Make Today
Much of the risk associated with heart disease can be reduced with lifestyle changes. The American Heart Association has developed a framework called Life’s Essential…
Exploring Novel Mechanisms in Chronic Lymphocytic Leukemia | Blood Cancers Today
Jeff P. Sharman, MD, discusses unmet needs, prognosis, and innovative treatments like pirtobrutinib in the evolving landscape of chronic lymphocytic leukemia.
How Socioeconomic Factors Impact Surgical Care for US Veterans With Early-Stage NSCLC | Docwire News
Though veterans with high socioeconomic deprivation experience less than optimal surgical care, they do not experience inferior long-term outcomes after surgery for NSCLC.
Blood test promises safer heart attack prevention
A simple scoring system could revolutionize how doctors prevent heart attacks and strokes by identifying patients most likely to benefit from preventive medications, according to…
RNA Inhibitor Olpasiran Dramatically Lowers High-Risk Cholesterol in Cardiovascular Disease Patients
A Phase II trial shows that the RNA inhibitor olpasiran reduces lipoprotein(a) levels by over 95%, potentially lowering cardiovascular risk.
Study questions clinical benefit of dexamethasone with axi-cel in LBCL patients
Prophylactic dexamethasone did not improve the safety or efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma (LBCL), according to a study presented…
